Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 274Lymphoid 15Gynecologic 10Thoracic 9Tumor-Agnostic 7Genitourinary 6Head & Neck 5Other hematologic neoplasm 4Breast 4Other solid neoplasm 3NET 2Endocrine 2Sarcoma 1Myeloid 1Dermatologic 1

Conditions

Neuroendocrine Tumors 2Vipoma 1Somatostatinoma 1Neoplasms 1Lung Neoplasms 1Insulinoma 1Glucagonoma 1Gastrinoma 1Carcinoma, Islet Cell 1Adenoma, Islet Cell 1

Interventions

Everolimus 25Magnetic Resonance Spectroscopy 13pembrolizumab 12pasireotide 12Sunitinib 11Octreotide 11lanreotide 10cabozantinib 10lenvatinib 8Sorafenib 8Cisplatin 8Temozolomide 7Etoposide 7Bevacizumab 7pazopanib 6Paclitaxel 6Nivolumab 6Doxorubicin 6Carboplatin 6Capecitabine 6vandetanib 5gallium Ga 68 dotatate 5Specimen Handling 5trametinib 4lutetium Lu 177 dotatate 4dabrafenib 4Mitotane 4Iodine-131 4telotristat ethyl 3surufatinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Oxaliplatin × Endocrine × Clear all
NCT00227617 2023-05-22

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

University of California, San Francisco

Phase 2/3 Terminated
36 enrolled 14 charts
EndocrineNETThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

NCT00398320 2017-03-01

Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors

Stanford University

Phase 2 Completed
40 enrolled 9 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡